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Copyright © 2009 JCBN Summary The prevalence of type 2 diabetes has been increased in Thais. Resistin is an
adipokine that involve in glucose homeostasis and is a candidate gene for type 2 diabetes. We
performed a case-control study in representative sample of 200 Thai volunteers, 105 controls
and 95 type 2 diabetes subjects. The purposes of the present study were to investigate the
association between two SNPs (single nucleotide polymorphisms) in the resistin gene, at posi-
tions +299(G>A) and −420(C>G), and biochemical parameters; to determine whether these
polymorphisms are linked to increased risk of type 2 diabetes. At position +299(G>A) of the
resistin gene, the resistin concentration among type 2 diabetes subjects was significantly higher
in GA/AA genotypes (3.40 ng/ml) than the GG genotype (1.99 ng/ml). Resistin gene poly-
morphism at position +299(G>A) in type 2 diabetes patients was significantly more frequent
than in the control group (p = 0.004). Polymorphism at position −420(C>G) showed no
significant relationship with type 2 diabetes (p = 0.095). Logistic regression analysis was shown
that +299(G>A) gene polymorphism was increased risk factors for type 2 diabetes (p = 0.013).
In conclusion, these finding suggest that resistin gene polymorphism at position +299(G>A)
has impact on the increased resistin concentrations and may influence susceptibility to type 2
diabetes in Thais.
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Introduction
The type 2 diabetes is increasing rapidly, and is becoming
a significant global health problem. White adipose tissue
secretes a variety of adipokines, which may provide the link
between insulin resistance and obesity, and resistin is one
such molecule [1, 2]. The human resistin gene is localized
to chromosome 19p13.3. Resistin suppressed adipocyte
differentiation by 80% in 3T3-L1 cells [3]; failure of
adipocyte differentiation has been suggested as a cause of
type 2 diabetes, possibly through an ectopic overload of fatty
acids and lipotoxicity of nonadipose tissues, such as muscles
and liver [4, 5]. The function of resistin related to glucose+299(G>A) Resistin Gene Polymorphism in Type 2 Diabetes
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homeostasis and insulin resistance in type 2 diabetes
patients, is not consistent. Some studies have reported
increased resistin expression levels in type 2 diabetes,
insulin resistance or obesity [6,  7], whereas some failed
to detect any change in resistin levels in these conditions
[8–10]. The results of studies investigating genetic varia-
tions in resistin, including single nucleotide polymorphisms
(SNPs), are controversial. The SNP on the resistin gene
promoter −420(C>G) has been associated with a prevalence
of type 2 diabetes [11], but not all reports have consistently
produced these findings [1]. Genetic variant at nucleotide
+299 (IVS2 +181(G>A) and obesity have been reported as
risk factors for type 2 diabetes in Caucasians [12]. However,
the findings for a Japanese type 2 diabetes population did not
concur [13]. Overall, some, but not all, studies have found
associations between resistin gene polymorphism, and type
2 diabetes. Therefore, the genetic variations of the resistin
gene in humans require clarification. The purposes of the
present study were to investigate the association between
two SNPs in the resistin gene, one promoter variant at
position −420(C>G) and one intron 2 variants at position
+299(G>A) from a translation start site, and the levels of
resistin, glucose, insulin, total cholesterol, triglycerides,
blood urea nitrogen, creatinine, blood pressure, and anthro-
pometric variables; to determine whether these poly-
morphisms are linked to increased risk of type 2 diabetes.
Materials and Methods
Study population
The case-control study comprised of 200 subjects allocated
into 2 groups. The first group was controls without type 2
diabetes (n = 105); the second group was type 2 diabetes
patients (n = 95). Diabetes was diagnosed based on the
American Diabetes Association criteria, reported in 2008
[14]. Subjects were excluded if they had severe hyper-
tension, liver, kidney, thyroid, cardiovascular or any active
inflammatory diseases, as well as receiving insulin. The
same medical doctor conducted the physical examinations
throughout the study and measured blood pressure (BP). The
type 2 diabetes subjects were volunteers from a diabetes
mellitus outpatient clinic of Burapha University Hospital,
Chonburi and Rajvithi Hospital, Bangkok, Thailand. The
protocol was approved by the Ethics Committee of Burapha
University and all participants agreeing to participate by
signing informed consent form.
Biological measurements
The body weight of each subjects was measured using a
carefully calibrated beam balance (Detecto®, Detecto Scale
Manufacturing, MO). Height was measured using a vertical
measuring rod. Body Mass Index (BMI) was conventionally
calculated as weight in kg/(height in meters)2. Waist and hip
circumferences were assessed and Waist and hip ratio
(WHR) was calculated.
About 10 ml of venous blood were taken from the sub-
jects in the morning, after overnight fast. Resistin concentra-
tions were determined by sandwich enzyme-linked immuno-
sorbent assay (sandwich ELISA) and insulin concentrations
by radioimmunoassay (Linco Research, Inc., MO.). Glucose,
blood urea nitrogen (BUN), creatinine, total cholesterol
(TC), and triglycerides (TG) were measured using enzymatic
methods by DADE Dimension ®AR.
Polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) technique
DNA was extracted from EDTA-treated whole blood by
Flexi Gene DNA kit (QIAGEN, Hilden, Germany). DNA-
fragments of the SNPs −420 and +299 were amplified by
PCR (PE Applied Biosystems) with the following primers—
(5'-3'): SNP −420 forward TGTCATTCTCACCCAGAGACA,
reverse TGGGCTCAGCTAACCAAATC, SNP + 299 for-
ward GAGAGGATCCAGGAGGTC, reverse GTGAGAC-
CAAACGGTCCCTG, as described by Kunnari et al. [15].
The PCR products were digested overnight with different
restriction enzymes. For SNP-420, 5 U of Bpi I, and for
SNP + 299 the Alu I restriction endonuclease, were used.
The digestion products were separated by 2% agarose gels
stained with ethidium bromide.
Statistical analysis
Statistical analyses were carried out using SPSS for
Windows version 11.5 (SPSS, Chicago, IL). The median,
range and 95% confidence interval (C.I.) were calculated.
The difference between groups was compared by using the
Mann-Whitney U-Wilcoxon Rank Sum W test. The difference
in genotypic frequencies of the two groups was assessed by
Chi-square test. The Minitab statistical computer program
was used to calculate the odds ratio (OR). To assess the
associated between type 2 diabetes as dependent variable
and potential factors, logistic regression was applied. A p
value<0.05 was considered statistically significant.
Results
The median and 95% confidence interval (C.I.) for age,
anthropometric variables, blood pressure, glucose, BUN,
creatinine, total cholesterol, triglycerides, insulin, and
resistin levels were shown in Table 1. Age, BMI, BUN and
blood pressure of type 2 diabetes group were not statistically
significantly different from those of control group. The
medians of waist/hip ratio, glucose, insulin, resistin,
creatinine and lipids were significantly higher in the type 2
diabetes than control subjects (p<0.050). The anthropo-
metric variables, blood pressure, and biochemical para-
meters of the type 2 diabetes subjects, for resistin poly-K. Suriyaprom et al.
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morphism genotypes at positions +299 and −420, were
shown in Table 2. With regard to +299(G>A) polymorphism
in type 2 diabetes subjects, there were no differences in
anthropometric variables, blood pressure or biochemical
parameters between the different genotypes, except for
resistin. Resistin concentrations were higher in the GA/AA
genotypes, heterozygous combined with homozygous mutant
types, than the GG genotype (wild type) (p<0.050).
Regarding to the −420(C>G) polymorphism in type 2
diabetes subjects, the data revealed no significant differ-
ences in any variable between the CG/GG genotypes
(heterozygous combined with homozygous mutant types)
and the CC genotype (wild type). The frequency of resistin
gene polymorphism at +299(G>A) and −420(C>G) in all
subjects were shown in Table 3. At +299(G>A) poly-
morphism, 31% of GA/AA genotype had type 2 diabetes,
and resistin gene polymorphism at this position were
significantly more frequent than in the control group
(p = 0.004). Polymorphism at position −420(C>G) showed
no significant relationship with type 2 diabetes (p =0 . 0 9 5 ) .
Logistic regression and odds ratios (OR) for possible
associations between type 2 diabetes and age, waist/hip
ratio and two resistin gene polymorphism at positions
+299(G>A) as well as −420(C>G) were shown in Table 4.
Three variables, age (OR = 1.1, p = 0.014), waist/hip ratio
(OR = 3.5, p = 0.020) and gene polymorphism at positions
+299(G>A) (OR = 2.3, p = 0.013), showed statistically
significant association. Table 5 showed the relationship
between hyperglycemia at cut off point > 126 mg/dl and
gene polymorphisms. There was a statistically significant
association between hyperglycemia and resistin gene poly-
morphism at positions +299(G>A) (p<0.05), except for the
position −420(C>G).
Table 1. Median and 95% confidence interval (C.I.) for age, anthropometric variables, blood pressure, and
biochemical parameters in control and type 2 diabetes
*p<0.05 by using Mann-Whitney U-Wilcoxon Rank Sum W test (Two-Tailed).
C.I., Confidence Interval.
Control Type 2 diabetes
p value





Age 55.0 57.0 0.099
(years) (53.0–58.0) (54.0–59.5)
BMI 24.7 26.2 0.437
(kg/m2) (24.0–25.5) (24.5–27.3)
Waist/hip ratio 0.87 0.92 0.000*
(0.86–0.88) (0.89–0.93)
Glucose 84 135 0.000*
(mg/dL) (78–86) (128–144)
Insulin 14.6 18.3 0.002*
(μU/dL) (12.5–15.1) (13.8–19.7)
Resistin 1.9 3.3 0.000*
(ng/mL) (1.2–2.1) (2.0–3.4)
BUN 13 13 0.293
(mg/dL) (11–13) (11–13)
Creatinine 0.8 1.0 0.001*
(mg/dL) (0.7–0.8) (0.8–1.0)
TG 124 164 0.000*
(mg/dL) (89–130) (120–180)
TC 207 242 0.000*
(mg/dL) (191–210) (216–247)
Systolic BP 129 134 0.260
(mmHg) (120–130) (130–138)
Diastolic BP 80 80 0.734
(mmHg) (80–84) (80–82)+299(G>A) Resistin Gene Polymorphism in Type 2 Diabetes
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Discussion
Many studies tried to elucidate the functions of resistin,
and reported that resistin may impair glucose tolerance,
insulin action, and decreased glucose uptake in skeletal
muscle cells [16,  17]. In mice, neutralizing resistin with
antibody improved insulin action and glucose uptake in diet-
induced obesity [2]. Resistin was four times more highly
expressed in human omental and abdominal subcutaneous
white adipocytes than in adipocytes from the thigh, sug-
gesting that human resistin could play a major role in
obesity-related insulin resistance [18]. It was well known
that most of type 2 diabetic patients were related to obesity
and insulin resistance. Some authors reported that serum
resistin levels were increased in type 2 diabetes subjects
[7, 19]. Such findings have been re-confirmed by this study.
Likewise, in Thai subjects, the type 2 diabetes group had
Table 2. Median and 95% confidence interval (C.I.) for age, anthropometric variables, blood pressure, and biochemical parameters in
type 2 diabetes.
*p<0.05 by Mann-Whitney U-Wilcoxon Rank Sum W test (two-tailed).
C.I., Confidence Interval.




p value (n =3 3 ) ( n =6 2 ) ( n = 35) (n =6 0 )
(95% C.I.) (95% C.I.) (95% C.I.) (95% C.I.)
Age 57.0 57.5 0.531 57.0 57.5 0.820
(years) (53.5–64.5) (53.8–59.2) (53.3–62.0) (53.9–60.1)
BMI 26.9 24.9 0.772 26.9 24.8 0.471
(kg/m2) (23.8–27.8) (24.1–27.3) (24.6–28.5) (23.7–27.3)
Waist/hipratio 0.93 0.92 0.353 0.91 0.92 0.598
(0.88–0.95) (0.89–0.93) (0.88–0.93) (0.89–0.93)
Glucose 130 136 0.239 131 143 0.349
(mg/dL) (126–145) (122–153) (122–139) (126–156)
Insulin 19.4 17.3 0.194 19.5 17.3 0.378
(μU/dL) (16.7–24.5) (12.5–19.1) (16.0–20.9) (12.9–20.0)
Resistin 2.0 3.4 0.035* 3.1 3.4 0.716
(ng/mL) (1.8–3.7) (2.2–3.7) (1.9–3.8) (2.0–3.7)
BUN 14 12 0.484 15 12 0.059
(mg/dL) (11–16) (10–13) (10–17) (11–13)
Creatinine 1.0 1.0 0.220 0.9 1.0 0.818
(mg/dL) (0.8–1.0) (0.8–1.1) (0.8–1.1) (0.8–1.1)
TG 177 159 0.667 164 164 0.590
(mg/dL) (116–225) (107–171) (111–194) (119–187)
TC 246 228 0.299 226 244 0.855
(mg/dL) (220–279) (197–244) (197–270) (216–253)
Systolic BP 130 136 0.861 139 130 0.273
(mmHg) (130–140) (126–141) (130–140) (126–138)
Diastolic BP 80 82 0.329 80 80 0.976
(mmHg) (79–80) (80–85) (75–83) (80–84)
Table 3. Genotype frequencies of +299(G>A) and −420(C>G)
polymorphisms in all subjects (n = 200)




Type 2 diabetes Control
GA/AA 31% 23.5% 0.004*
(n = 62) (n = 47)
GG 16.5% 29%
(n = 33) (n = 58)
SNP-42O Type 2 diabetes Control p valuea
CG and GG 30% 27% 0.095
(n = 60) (n = 54)
CC 17.5% 25.5%
(n = 35) (n = 51)K. Suriyaprom et al.
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higher waist/hip ratio and resistin levels than the control
group so it could be indicated that type 2 diabetes mellitus
was associated with increased central obesity. In contrast,
other studies found no difference in plasma resistin levels
between patients with type 1 and type 2 diabetes, and
healthy controls [20]. Studies have reported no association
between resistin levels and markers of insulin resistance in
type 2 diabetes patients [8, 21]. Therefore, the true function
of resistin requires further study.
The human resistin gene is localized on chromosome 19.
Results of studies investigating genetic variations in the
resistin gene were controversial. Our observations found
an association between resistin gene polymorphism at
+299(G>A) in type 2 diabetes and higher resistin concentra-
tion, but not in subjects carrying CG/GG resistin gene
genotypes at −420(C>G). In a Japanese population, the −420
GG genotype was associated with type 2 diabetes; the −420
GG resistin genotype was related to increased promoter
activity through specific Sp1/3 binding, which in turn, leads
to increased resistin levels and increased risk of type 2
diabetes [11]. However, the current study found that poly-
morphism at −420(G>C) was not significantly associated
with increased risk of type 2 diabetes. Conneely et al. failed
to detect any correlation between resistin gene promoter
polymorphism at −420(G>C) and type 2 diabetes [1]. No
association between SNP of the resistin gene in the promoter
region with obesity or insulin resistance was found [22]. Our
study did not find a significantly increased risk of type 2
diabetes in resistin gene polymorphism at position −420
(C>G), and similar data were reported by Engert et al. [23].
In Caucasians, a resistin genotype at position +299(G>A)
and obesity was a significant determinant of type 2 diabetes
risk [12] whereas resistin gene +299(G>A) was not
associated with type 2 diabetes in Japanese subjects [13].
This polymorphism is in an intron, +299(G>A), which
generally has not been considered to have regulatory func-
tions. However, it has been shown that SNPs in the non-
coding region, such as the 3'-untranslated gene region, can
affect gene expression [24]. Intron polymorphism of TFAP2B,
a susceptibility gene to type 2 diabetes, influenced adipo-
cytokine gene expression transcriptional activity [25].
Therefore, resistin gene polymorphism at +299(G>A) may
be a marker in linkage disequilibrium with an other poly-
morphism affecting gene expression. Resistin gene poly-
morphism at +299(G>A) in Thai diabetic subjects may
contribute to increased resistin levels, which may be
involved in the pathogenesis of type 2 diabetes by impaired
insulin action. Logistic regression analysis of this study
showed that +299(G>A) polymorphism, age and waist/hip
ratio were linked to significantly increased risk of type 2
diabetes in Thais. The inconsistencies of resistin gene poly-
morphism among studies might be explained by the different
genetic backgrounds or environmental conditions of the
population studied. Furthermore, our study showed that
there was a statistically significant association between
hyperglycemia and resistin gene polymorphism at positions
+299(G>A). Kiritoshi et al., showed that hyperglycemia
increased reactive oxygen species produced by mito-
chondria, resulting in activation of nuclear factor κB, induc-
tion of cyclooxygenase-2 gene expression. These results
might contribute to the pathogenesis of diabetic complica-
tions especially diabetic nephropathy [26]. Astaxanthin was
a carotenoid that might scavenge the production of reactive
oxygen species in mitochondria and has protective effects on
diabetic nephropathy [27]. Therefore, type 2 diabetes should
control the level of blood glucose and Gymnema sylvestre
was one of alternative herbal medicines that might help to
treat diabetes mellitus by preventing the sugar molecules
absorption in the intestine [28].
In summary, we found that type 2 diabetic subjects dis-
played a significantly increased resistin concentration than
controls and the levels of resistin in type 2 diabetes with
GA/AA genotypes were significantly higher than those with
Table 4. Logistic regression analysis when type 2 diabetes was used as dependent variable and
age, waist/hip ratio and resistin gene polymorphism at +299(G>A) as well as at −420
(C>G) were taken as independent variables.
*p<0.05
C.I., Confidence Interval
Variables β Odds ratios Exp (β) (95% C.I.) p value
gene +299(G>A) 0.811 2.3 1.2–4.3 0.013*
gene −420(C>G) 0.175 1.2 0.7–2.3 0.593
age 0.045 1.1 1.0–1.2 0.014*
waist/hip ratio 1.241 3.5 1.2–9.9 0.020*
Table 5. The relationship between hyperglycemia and gene
polymorphisms when hyperglycemia (cut off point>126
mg/dl) was used as dependent variable.
*p<0.05
Variables Odds ratios Exp (β) p value
gene +299(G>A) 1.930 0.042*
gene −420(C>G) 1.609 0.142+299(G>A) Resistin Gene Polymorphism in Type 2 Diabetes
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the GG genotype. The resistin gene polymorphism at
+299(G>A) appeared to affect susceptibility to type 2 dia-
betes, especially among Thais, whereas −420(C>G) poly-
morphism was unlikely to play a major function in the
etiology of type 2 diabetes among the Thai population.
Moreover, we found that waist/hip ratio and age were also
significantly associated with increased risk of type 2 dia-
betes. Further studies are needed to fully clarify the role of
the resistin gene in type 2 diabetes, by investigation of other
populations including large population-sample sizes, and
how resistin polymorphism at +299(G>A) affects gene
expression.
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